CoreBone has developed, and is distributing, bioactive, coral-based bone graft material that provides a natural alternative to human and animal-derived (bovine, porcine) bone grafts.
CoreBone has developed a highly bioactive, strong, and resorbable bone graft material. The patented technology embeds bioactive minerals (e.g., silicium) into the skeleton of corals during their growth process to accelerate healing and provide better connectivity. It offers the same bonelike qualities as organic material (human/animal derived) without the associated risks.
CoreBone’s strictly controlled growing environment in its coral farm preserves the coral’s natural, bonelike properties.
CoreBone’s coral-based material offers —
Stage: Revenue; sales in France, Poland, Israel
Founded: December 2011
Investors: The Trendlines Group; private investors in Israel, United States, and Singapore; founders
IP: U.S. patent (2015) and Israeli patent; EU patent pending
September 2017 update
CoreBone continues to expand sales. CoreBone developed a natural alternative to human and animal-derived bone grafts. The Company’s bone-like graft is made from the pure mineral exoskeleton of corals grown in a controlled environment and using a patented process.
“We presented our products at the largest dental show in Cologne, Germany,” says CEO Ohad Schwartz, ” and received very positive feedback from visitors and distributors. Opinion leaders confirmed that the CoreBone material compares to the gold standard for dental bone graft. However, since we are not a bovine-derived product, our material is better replaced by bone (remodeling ) and appeals to segments (and countries) that are opposed to using human or animal derivatives.
“We are currently selling in France, Poland, Israel, and soon Romania, and have received distribution requests from other countries — and doctors — around the world. We signed a distribution agreement with a top dental implant company and give regular training sessions to customers and distributors. In this month alone, we are shipping 1,000 units.”
CoreBone earned CE mark and AMAR approval (from Israel’s Ministry of Health) to market its products in Israel and worldwide to the dental and orthopedic markets.
Today, implants are used more and more in dental and orthopedics. In many cases, bone is insufficient, and bone grafts stimulate the growth of new bone to support and anchor the implant. Most bone graft materials in the market are derived from human and animal bone and carry the risk of disease and rejection. *Furthermore, bovine-derived products hardly remodel due to the heat treatment that is essential to reduce viral risks. Synthetic materials, a fast-growing segment, lack strength.
Bone grafts from human and animal origin are in decline due to their associated risks. The synthetic bioactive product share is growing as the market seeks alternatives. The global market for orthopedic bone graft substitutes is expected to reach $3.4 billion by 2022 (Allied Market Research). According to Transparency Market Research, the global dental membrane and bone graft substitutes market is expected to reach $922.6 million by 2024.
Minimally invasive treatment of heart valve disease
A more efficient ablation catheter to treat atrial fibrillation
Preventing the development of pressure sores
Novel treatment for vertebral compression fractures
Preventing catheter-associated urinary tract infections (CAUTIs)
Wireless, wearable vital sign monitoring system
Cryotherapy for superficial bladder cancer